DexCom, Inc. (NASDAQ:DXCM) Director Nicholas Augustinos Sells 2,618 Shares

DexCom, Inc. (NASDAQ:DXCM) Director Nicholas Augustinos sold 2,618 shares of the business’s stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $81.69, for a total value of $213,864.42. Following the transaction, the director now directly owns 37,083 shares in the company, valued at $3,029,310.27. This trade represents a 6.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Nicholas Augustinos also recently made the following trade(s):

• On Monday, June 16th, Nicholas Augustinos sold 3,672 shares of DexCom stock. The stock was sold at an average price of $82.80, for a total value of $304,041.60.

DexCom Trading Down 1.4%

NASDAQ:DXCM opened at $81.83 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $117.49. The business has a 50 day simple moving average of $79.25 and a 200 day simple moving average of $79.38. The firm has a market capitalization of $32.09 billion, a P/E ratio of 61.07, a P/E/G ratio of 1.77 and a beta of 1.46.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter last year, the firm posted $0.32 EPS. The company’s revenue was up 12.5% compared to the same quarter last year. Equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on DXCM. Robert W. Baird dropped their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, May 2nd. Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Citigroup reiterated a “buy” rating and issued a $102.00 price target (up from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Barclays boosted their price target on DexCom from $90.00 to $93.00 and gave the company an “equal weight” rating in a report on Monday, May 5th. Finally, Cfra Research upgraded DexCom to a “hold” rating in a report on Friday, March 21st. Four analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $98.50.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in DXCM. Brighton Jones LLC boosted its position in DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after acquiring an additional 11,946 shares during the period. Empowered Funds LLC boosted its position in DexCom by 37.0% during the 4th quarter. Empowered Funds LLC now owns 8,010 shares of the medical device company’s stock worth $623,000 after acquiring an additional 2,163 shares during the period. Allspring Global Investments Holdings LLC boosted its position in DexCom by 28.8% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 58,571 shares of the medical device company’s stock worth $4,596,000 after acquiring an additional 13,111 shares during the period. Van ECK Associates Corp boosted its position in DexCom by 325.0% during the 4th quarter. Van ECK Associates Corp now owns 85,813 shares of the medical device company’s stock worth $6,674,000 after acquiring an additional 65,622 shares during the period. Finally, Bank Pictet & Cie Europe AG boosted its position in DexCom by 1.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company’s stock worth $8,637,000 after acquiring an additional 2,010 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.